Patel Dhavalkumar Dhirajlal reported option exercise involving 125,000 derivative units of Sana Biotechnology, Inc. at $0.00 for $0 on Aug 26, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
EVP, Chief Scientific Officer
EVP, Chief Scientific Officer
Filed Aug 27, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
125,000Restricted Stock Units
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
250,000Direct
Trade date
Aug 26, 2026Option exercise
Filed
Aug 27, 2026, 4:21 PM ET1-day reporting delay
Accession
0002115339-26-000004Code M · Transaction 108992
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Aug 26, 2026Option exercise125,000$0.00$0Trade 108990
Aug 27, 2026Tax withholding41,158$4.11−$169,159.38Trade 108991
3 transaction rows in this filing. Joint filers share the same rows.

SANA price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
SANA · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago1d ago
Returns since7d −4.2%30d −28%90d180d1y

Footnotes in full

F1: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechology, Inc. ("Sana") common stock. F2: The award vested as to 25% of the restricted stock units on each of August 26, 2025 and 2026, and the remaining restricted stock units will vest in two equal installments on each of August 26, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.